ANNJI PHARMACEUTICAL CO., LTD.
🇹🇼Taiwan
- Country
- 🇹🇼Taiwan
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.ajpharm.com
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AJ302-IM in Healthy Volunteers
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- AnnJi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT06625541
- Locations
- 🇺🇸
AnnJi Investigational Site, Miami, Florida, United States
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients
Phase 1
Completed
- Conditions
- Spinal and Bulbar Muscular AtrophyKennedy's Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- AnnJi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT05517603
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Washington University in St. Louis, Saint Louis, Missouri, United States
🇺🇸National Institutes of Health, Bethesda, Maryland, United States
A Study to Investigate the Safety, Tolerability, Pharmacokinetics of ALZ002 DS in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: ALZ002 DSDrug: Placebo
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- AnnJi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT04392830
- Locations
- 🇦🇺
Cmax clinical research, Adelaide, Australia
© Copyright 2025. All Rights Reserved by MedPath